NO178889C - [(Arylalkylpiperidin-4-yl)metylÅ-2a,3,4,5-tetrahydro-1(2H)-acenaftylen-1-oner og beslektede forbindelser - Google Patents

[(Arylalkylpiperidin-4-yl)metylÅ-2a,3,4,5-tetrahydro-1(2H)-acenaftylen-1-oner og beslektede forbindelser

Info

Publication number
NO178889C
NO178889C NO922223A NO922223A NO178889C NO 178889 C NO178889 C NO 178889C NO 922223 A NO922223 A NO 922223A NO 922223 A NO922223 A NO 922223A NO 178889 C NO178889 C NO 178889C
Authority
NO
Norway
Prior art keywords
loweralkoxy
hydrogen
arylalkylpiperidin
acenaphthylen
methyla
Prior art date
Application number
NO922223A
Other languages
English (en)
Norwegian (no)
Other versions
NO922223D0 (no
NO922223L (no
NO178889B (no
Inventor
Jr Raymond Walter Kosley
Bettina Spahl
Original Assignee
Hoechst Marion Roussel Inc
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc, Hoechst Roussel Pharma filed Critical Hoechst Marion Roussel Inc
Publication of NO922223D0 publication Critical patent/NO922223D0/no
Publication of NO922223L publication Critical patent/NO922223L/no
Publication of NO178889B publication Critical patent/NO178889B/no
Publication of NO178889C publication Critical patent/NO178889C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO922223A 1991-06-07 1992-06-05 [(Arylalkylpiperidin-4-yl)metylÅ-2a,3,4,5-tetrahydro-1(2H)-acenaftylen-1-oner og beslektede forbindelser NO178889C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/713,249 US5106856A (en) 1991-06-07 1991-06-07 [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds

Publications (4)

Publication Number Publication Date
NO922223D0 NO922223D0 (no) 1992-06-05
NO922223L NO922223L (no) 1992-12-08
NO178889B NO178889B (no) 1996-03-18
NO178889C true NO178889C (no) 1996-06-26

Family

ID=24865395

Family Applications (1)

Application Number Title Priority Date Filing Date
NO922223A NO178889C (no) 1991-06-07 1992-06-05 [(Arylalkylpiperidin-4-yl)metylÅ-2a,3,4,5-tetrahydro-1(2H)-acenaftylen-1-oner og beslektede forbindelser

Country Status (23)

Country Link
US (1) US5106856A (da)
EP (1) EP0517221B1 (da)
JP (1) JP2961013B2 (da)
KR (1) KR100234445B1 (da)
AT (1) ATE131814T1 (da)
AU (1) AU646784B2 (da)
CA (1) CA2070714A1 (da)
CZ (1) CZ284591B6 (da)
DE (1) DE69206889T2 (da)
DK (1) DK0517221T3 (da)
ES (1) ES2081517T3 (da)
FI (1) FI101297B (da)
GR (1) GR3018558T3 (da)
HU (1) HU217967B (da)
IE (1) IE72199B1 (da)
IL (1) IL102118A (da)
MX (1) MX9202736A (da)
NO (1) NO178889C (da)
NZ (1) NZ243013A (da)
PL (1) PL169423B1 (da)
RU (1) RU2043989C1 (da)
TW (1) TW206214B (da)
ZA (1) ZA924109B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW248556B (da) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
US6939879B2 (en) * 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
CN1572299A (zh) 1998-09-30 2005-02-02 武田药品工业株式会社 改善膀胱排泄能力的药物
CN109662964A (zh) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
JP5916746B2 (ja) 2010-11-15 2016-05-11 エージンバイオ, インコーポレイテッド 認知障害を処置するためのピリダジン誘導体、組成物、および方法
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CN106068256B (zh) 2013-12-20 2020-10-23 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ, インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7514534B2 (ja) 2018-06-19 2024-07-11 エージンバイオ, インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2589934A (en) * 1950-08-24 1952-03-18 Abbott Lab 2-aminomethyl-tetrahydroacenapthones-1 and their preparation
US3391178A (en) * 1964-12-30 1968-07-02 Ernest E. Campaigne Dialkylaminoalkyl 1-oxo-2alpha, 3, 4, 5-tetrahydroacenaphthen-2alpha-carboxylates
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2969359B2 (ja) * 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物

Also Published As

Publication number Publication date
IL102118A0 (en) 1993-01-14
NO922223D0 (no) 1992-06-05
DE69206889T2 (de) 1996-05-30
ES2081517T3 (es) 1996-03-16
CS171392A3 (en) 1992-12-16
EP0517221B1 (en) 1995-12-20
AU646784B2 (en) 1994-03-03
TW206214B (da) 1993-05-21
KR100234445B1 (ko) 1999-12-15
KR930000483A (ko) 1993-01-15
JPH06116237A (ja) 1994-04-26
PL294803A1 (en) 1993-07-26
ZA924109B (en) 1993-02-24
PL169423B1 (pl) 1996-07-31
EP0517221A1 (en) 1992-12-09
IE72199B1 (en) 1997-04-09
AU1801592A (en) 1992-12-10
GR3018558T3 (en) 1996-03-31
US5106856A (en) 1992-04-21
IE921840A1 (en) 1992-12-16
FI922592A (fi) 1992-12-08
DK0517221T3 (da) 1996-04-22
NO922223L (no) 1992-12-08
HUT65605A (en) 1994-07-28
HU9201887D0 (en) 1992-08-28
NZ243013A (en) 1995-04-27
FI101297B1 (fi) 1998-05-29
DE69206889D1 (de) 1996-02-01
CA2070714A1 (en) 1992-12-08
IL102118A (en) 1996-05-14
HU217967B (hu) 2000-05-28
RU2043989C1 (ru) 1995-09-20
FI101297B (fi) 1998-05-29
NO178889B (no) 1996-03-18
ATE131814T1 (de) 1996-01-15
JP2961013B2 (ja) 1999-10-12
CZ284591B6 (cs) 1999-01-13
FI922592A0 (fi) 1992-06-04
MX9202736A (es) 1993-01-01

Similar Documents

Publication Publication Date Title
NO178889C (no) [(Arylalkylpiperidin-4-yl)metylÅ-2a,3,4,5-tetrahydro-1(2H)-acenaftylen-1-oner og beslektede forbindelser
NO921490L (no) 1-(pyrido(3,4-b)-1,4-oksazinyl-4-yl)-1h-indoler, mellomprodukter og fremgangsmaate for fremstilling derav samt anvendelse som medikamenter
NZ222640A (en) Quinolinol derivatives and pharmaceutical compositions
FI896243A0 (fi) N-pyridinyl-9h-karbazol-9-aminer, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
NO902813L (no) (1,2,3,4-tetrahydro-9-acridinimino)cykloheksankarboksylsyre og relaterte forbindelser, fremgangsmaate for fremstilling og anvendelse som medikamenter.
NO902556D0 (no) 4,5,5a,6-tetrahydro-3h-isoksazol(5,4,3-kl)akridinderivater og fremgangsmaate for fremstilling derav.
ES2079530T3 (es) 1-(piridinilalquil)-1h-indoles, -indolinas y compuestos analogos relacionados.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN DECEMBER 2000